44. Ong DK, Mitchell SB, Barrett JS, et al. Manipulation of dietary short chain carbohydrates alters the pattern of gas production and genesis of symptoms in irritable bowel syndrome. *J Gastroenterol Hepatol*. 2010 Aug;25(8):1366–1373.
45. Nieves R, Jackson RT. Specific carbohydrate diet in treatment of inflammatory bowel disease. *Tenn Med*. 2004 Sep;97(9):407.
46. Choung RS, Ruff KC, Malhotra A, et al. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. *Aliment Pharmacol Ther*. 2011 May;33(9):1059–1067. doi: 10.1111/j.1365-2036.2011.04625.x. Epub 2011 Mar 13.
47. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. *J Hum Nutr Diet*. 2011 Oct;24(5):487–495. doi:10.1111/j.1365-277X.2011.01162.x. Epub 2011 May 25.
48. Pimentel M, Constantino T, Kong Y, Bajwa M, Rezaei A, Park S. A 14-day elemental diet is highly effective in normalizing the lactulose breath test. *Dig Dis Sci*. 2004 Jan;49(1):73–77.
49. Scarpignato C, Pelosini I. Experimental and clinical pharmacology of rifaximin, a gastrointestinal selective antibiotic. *Digestion*. 2006;73 Suppl 1:13–27. Epub 2006 Feb 8.
50. Lombardo L, Foti M, Ruggia O, Chiecchio A. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. *Clin Gastroenterol Hepatol*. June 2010;8(6):504–508.
51. Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. *N Engl J Med*. 2011 Jan 6;364(1):22–32.
52. Yang J, Lee HR, Low K, Chatterjee S, Pimentel M. Rifaximin versus other antibiotics in the primary treatment and retreatment of bacterial overgrowth in IBS. *Dig Dis Sci*. 2008 Jan;53(1):169–74. Epub 2007 May 23.
53. Debbia EA, Maioli E, Roveta S, Marchese A. Effects of rifaximin on bacterial virulence mechanisms at supra- and sub-inhibitory concentrations. *J Chemother*. 2008 Apr;20(2):186–194.
54. Mencarelli A, Renga B, Palladino G, et al. Inhibition of NF-κβ by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. *Eur J Pharmacol*. 2011 Oct 1;668(1–2):317–324. Epub 2011 Jul 26.
55. Low K, Hwang L, Hua J, Zhu A, Morales W, Pimentel M. A combination of rifaximin and neomycin is most effective in treating irritable bowel syndrome patients with methane on lactulose breath test. *J Clin Gastroenterol*. 2010 Sep;44(8):547–550.
56. Logan AC, Beaulne TM. The treatment of small intestinal bacterial overgrowth with enteric-coated peppermint oil: a case report. *Altern Med Rev*. 2002 Oct;7(5):410–417.
57. Pimentel M, Morales W, Lezcano S, Sun-Chuan D, Low K, Yang J. Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth. *Gastroenterol Hepatol (N Y)*. 2009 Jun;5(6):435–442.
58. Pimentel M. An evidence-based treatment algorithm for IBS based on a bacterial/SIBO hypothesis: Part 2. Am J Gastroenterol. 2010 Jun;105(6):1227–30.
59. Ploesser J, Weinstock LB, Thomas E. Low Dose Naltrexone: Side Effects and Efficacy in Gastrointestinal Disorders. International Journal of Pharmaceutical Compounding; March 2010.
60. Manabe N, Rao AS, Wong BS, Camilleri M. Emerging pharmacologic therapies for irritable bowel syndrome. Curr Gastroenterol Rep. 2010 Oct;12(5):408–16.
61. Gibson PR, Shepherd SJ. Evidence-based dietary management of functional gastrointestinal symptoms: The FODMAP approach. J Gastroenterol Hepatol. 2010 Feb;25(2):252–8. Review.
62. Bowman, G. The Gut, the Brain and the Functional GI Disorders. Functional Gastroenterology Seminar: Level 1. Winter 2010, p. 19.
63. Gabrielli M, Lauritano EC, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G, Silveri NG, Gasbarrini A. Bacillus clausii as a treatment of small intestinal bacterial overgrowth. Am J Gastroenterol. 2009 May;104(5):1327–8. Epub 2009 Apr 7.
64. Soifer LO, Peralta D, Dima G, Besasso H. Comparative clinical efficacy of a probiotic vs. an antibiotic in the treatment of patients with intestinal bacterial overgrowth and chronic abdominal functional distension: a pilot study. Acta Gastroenterol Latinoam. 2010 Dec;40(4):323–7.
65. Schiffrin EJ, Parlesak A, Bode C, Bode JC, van't Hof MA, Grathwohl D, Guigoz Y. Probiotic yogurt in the elderly with intestinal bacterial overgrowth: endotoxaemia and innate immune functions. Br J Nutr. 2009 Apr;101(7):961–6.
66. Ruland J. Return to homeostasis: downregulation of NF-κB responses. Nat Immunol. 2011 Jun 19;12(8):709–14. doi: 10.1038/ni.2055.
67. Al-Sadi RM, Ma TY. IL-1beta causes an increase in intestinal epithelial tight junction permeability. J Immunol. 2007 Apr 1;178(7):4641–9.
68. Csaki C, Mobasheri A, Shakibaei M. Synergistic chondroprotective effects of curcumin and resveratrol in human articular chondrocytes: inhibition of IL-1beta-induced NF-kappaB-mediated inflammation and apoptosis. Arthritis Res Ther. 2009;11(6):R165. Epub 2009 Nov 4.
69. Chou J, Tabrizi R, Pimentel M, Sokol T. S1326 Presumed IBS Subjects With Short Remission After Antibiotic Therapy Often Have Secondary Causes for Their Symptoms. Gastroenterology, Volume 138, Issue 5, Supplement 1 , Pages S–229, May 2010.

Allison Siebecker, ND, MSOM, LAc
Steven Sandberg-Lewis, ND, DHANP
NCNM Clinic
3025 SW Corbett Ave.
Portland, Oregon 97211

◆

Allison Siebecker, ND, MSOM, LAc, is a graduate of NCNM, where she specializes in treating SIBO in her private practice. She is the author of an educational website on SIBO, is currently writing a book on SIBO, and teaches continuing education to physicians on SIBO and related topics. In 2005, Dr. Siebecker received the Best in Naturopathy award from the *Townsend Letter* for her article "Traditional Bone Broth in Modern Health and Disease." Visit her educational website at www.siboinfo.com.

Steven Sandberg-Lewis, ND, DHANP, is a graduate of NCNM, where he practices, supervises student shifts, and has been professor of gastroenterology since 1996. In 2009, Dr Sandberg-Lewis received the Best in Naturopathy award from the Townsend Letter for his article "Hiatal Hernia Syndrome" and honorable mention in 2011 for his article "Proton Pump Inhibitors – A Risky Experiment?" His textbook, *Functional Gastroenterology*, is available at www.ncnm.edu/bookstore.